P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells

References

• McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1(2):130–141.
   PubMed Web of Science ®Google Scholar
• Dachs GU, Dougherty GJ, Stratford IJ, et al. Targeting gene therapy to cancer: a review. Oncol Res. 1996;9(6–7):313–325.
   Web of Science ®Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750–763.
   PubMed Web of Science ®Google Scholar
• Zangemeister-Wittke U, Leech SH, Olie RA, et al, A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res. 2000;6(6):2547–2555.
   PubMed Web of Science ®Google Scholar
• Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Science. 2006;97(8):689–696.
   PubMed Web of Science ®Google Scholar
• Rao DD, Vorhies JS, Senzer N, et al. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 2009;61(9):746–759.
   PubMed Web of Science ®Google Scholar
• Devi G. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 2006;13(9):819–829.
   PubMed Web of Science ®Google Scholar
• Paddison PJ, Caudy AA, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002;16(8):948–958.
   PubMed Web of Science ®Google Scholar
• Whitelaw B. VIRAL AND NONVIRAL VECTORS. Reproduction. Fertil Dev. 2012;25(1):317–17.
   Web of Science ®Google Scholar
• Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev. 2008;109(2):259–302. **An overview article provides an exhaustive account on nonviral vectors for gene delivery
   Web of Science ®Google Scholar
• Templeton NS, Lasic DD, Frederik PM, et al. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997;15(7):647–652.
   PubMed Web of Science ®Google Scholar
• De Smedt SC, Demeester J, Hennink WE. Cationic polymer based gene delivery systems. Pharm Res. 2000;17(2):113–126.
   PubMed Web of Science ®Google Scholar
• Simeoni F, Morris MC, Heitz F, et al. Insight into the mechanism of the peptide‐based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 2003;31(11):2717–2724.
   PubMed Web of Science ®Google Scholar
• Bowne WB, Michl J, Bluth MH, et al. Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer. Cancer Ther. 2007;5:331.
   Google Scholar
• Lungwitz U, Breunig M, Blunk T, et al. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharmaceutics Biopharmaceutics. 2005;60(2):247–266.
   PubMed Web of Science ®Google Scholar
• Park IK, Lasiene J, Chou SH, et al. Neuron‐specific delivery of nucleic acids mediated by Tet1‐modified poly (ethylenimine). J Gene Med. 2007;9(8):691–702.
   PubMed Web of Science ®Google Scholar
• Tian H, Lin L, Chen J, et al. RGD targeting hyaluronic acid coating system for PEI-PBLG polycation gene carriers. J Controlled Release. 2011;155(1):47–53.
   PubMed Web of Science ®Google Scholar
• Moffatt S, Wiehle S, Cristiano RJ. Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13. Hum Gene Ther. 2005;16(1):57–67.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351(6326):453–456.
   PubMed Web of Science ®Google Scholar
• Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1(14):1001–1008.
   PubMed Web of Science ®Google Scholar
• Do TN, Rosal RV, Drew L, et al, Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene. 2003;22(10):1431–1444.
   PubMed Web of Science ®Google Scholar
• Sarafraz-Yazdi E, Bowne WB, Adler V, et al., Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci. 2010;107(5):1918–1923.
   PubMed Web of Science ®Google Scholar
• Michl J, Scharf B, Schmidt A, et al., PNC–28, a p53–derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006;119(7):1577–1585.
   PubMed Web of Science ®Google Scholar
• Sookraj KA, Bowne WB, Adler V, et al., The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemother Pharmacol. 2010;66(2):325–331.
   PubMed Web of Science ®Google Scholar
• Bowne WB, Sookraj KA, Vishnevetsky M, et al., The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol. 2008;15(12):3588–3600.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Parhiz B, Hatefi A, et al. Modified polyethyleneimine with histidine–lysine short peptides as gene carrier. Cancer Gene Ther. 2010;18(1):12–19.
   PubMed Web of Science ®Google Scholar
• Parhiz H, Hashemi M, Hatefi A, et al. Arginine-rich hydrophobic polyethylenimine: potent agent with simple components for nucleic acid delivery. Int J Biol Macromol. 2013;60:18–27.
   PubMed Web of Science ®Google Scholar
• Bai J, Açan B, Ghahary A, et al. (ethyleneimine)/arginine–glycine–aspartic acid conjugates prepared with N‐succinimidyl 3‐(2‐pyridyldithio) propionate: An investigation of peptide coupling and conjugate stability. J Polymer Sci A: Polymer Chem. 2004;42(23):6143–6156.
   Web of Science ®Google Scholar
• Lee J, Boczkowski D, Nair S. Programming human dendritic cells with mRNA. In: Rabinovich PM, editor. Synthetic messenger RNA and cell metabolism modulation: methods and protocols, methods in molecular biology. New York (NY): Humana Press; 2013. p. 111–125.
   Google Scholar
• Manna P, Jain S. Effect of PIP3 on adhesion molecules and adhesion of THP-1 monocytes to HUVEC treated with high glucose. Cell Physiol Biochem. 2014;33(4):1197–1204.
   PubMed Web of Science ®Google Scholar
• Shahidi‐Hamedani N, Shier WT, Moghadam Ariaee F, et al. Targeted gene delivery with noncovalent electrostatic conjugates of sgc‐8c aptamer and polyethylenimine. J Gene Med. 2013;15(6–7):261–269.
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–3666.
   PubMed Web of Science ®Google Scholar
• Oskuee RK, Dehshahri A, Shier WT, et al. Alkylcarboxylate grafting to polyethylenimine: a simple approach to producing a DNA nanocarrier with low toxicity. J Gene Med. 2009;11(10):921–932.
   PubMed Web of Science ®Google Scholar
• Putral LN, Gu W, McMillan N. RNA interference for the treatment of cancer. Drug News Perspect. 2006;19(6):317–324.
   PubMed Web of Science ®Google Scholar
• McAnuff MA, Rettig GR, Rice KG. Potency of siRNA versus shRNA mediated knockdown in vivo. J Pharm Sci. 2007;96(11):2922–2930.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Nishikawa M, Kawakami S, et al., Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. Mol Ther. 2003;7(2):254–261.
   PubMed Web of Science ®Google Scholar
• Sadeqzadeh E, Rahbarizadeh F, Ahmadvand D, et al. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J Controlled Release. 2011;156(1):85–91.
   PubMed Web of Science ®Google Scholar
• Yang J-Y, Zong CS, Xia W, et al., MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol. 2006;26(19):7269–7282.
   PubMed Web of Science ®Google Scholar
• Schon O, Friedler A, Bycroft M, et al. Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol. 2002;323(3):491–501.
   PubMed Web of Science ®Google Scholar
• Son S, Namgung R, Kim J, et al. Bioreducible polymers for gene silencing and delivery. Acc Chem Res. 2011;45(7):1100–1112.
   PubMed Web of Science ®Google Scholar
• Xie Y-E, Tang E-J, Zhang D-R, et al. Down-regulation of Bcl-XL by RNA interference suppresses cell growth and induces apoptosis in human esophageal cancer cells. World J Gastroenterol. 2006;12(46):7472.
   PubMed Web of Science ®Google Scholar
• Fiebig AA, Zhu W, Hollerbach C, et al. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer. 2006;6(1):213.
   PubMed Web of Science ®Google Scholar
• Yang J, Sun M, Zhang A, et al. Adenovirus-mediated siRNA targeting Bcl-xL inhibits proliferation, reduces invasion and enhances radiosensitivity of human colorectal cancer cells. World J Surg Oncol. 2011;9(1):117.
   PubMed Web of Science ®Google Scholar
• España L, Fernández Y, Rubio N, et al. Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res Treat. 2004;87(1):33–44.
   PubMed Web of Science ®Google Scholar